



New Quinoxalines with Biological Applications

Mónica Vieira¹, Ricardo Ferraz^{1*}, Rúben Fernandes^{1,2} and Cristina Prudêncio^{1,2,3}

¹Ciências Químicas e Biomoléculas, Escola Superior de Tecnologia da Saúde – Instituto Politécnico do Porto, Rua Valente Perfeito, Portugal

²Centro de Farmacologia e Biopatologia Química (U38-FCT), Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernâni Monteiro, Portugal

³USF Abel Salazar, ARS Norte, Portugal

In search of alternatives to antimicrobial agents currently in use, and in order to respond to the landscape of loss of efficacy due to the emergence of resistance, several research groups are evaluating several families of compounds, among them the quinoxaline derivatives family, which presented several other potential biological applications.

Quinoxaline derivatives are an important class of heterocyclic compounds, where N replaces some carbon atoms in the ring. Quinoxaline molecular formula is C₈H₆N₂ and is formed by two aromatic rings, benzene and pyrazine. It is rare in natural state, but their synthesis is easy to perform [1]. Modifying its structure is possible to obtain a wide variety of compounds with different biological properties.

In the last two decades, several quinoxaline derivatives have been tested and presented antimicrobial activity, as antifungal [2-4] and antibacterial agents [2-13]. The antibacterial activity observed covers both Gram-negative and Gram-positive bacteria [6,8,11-13], including *Mycobacterium* species [4,7,9,10,14,15]. There are also data pointing to activity against multidrug resistant *Mycobacterium tuberculosis* [15]. Several studies have been described, concerning synthesis and biological activity of a large amount of quinoxalines. Some quinoxaline 1,4-di-N-oxide derivatives have been shown to inhibit *M. tuberculosis* to a rate of 99 to 100% [9,16].

Antifungal activity for quinoxaline derivatives has been tested against *Candida albicans* [17,18]. Thieno[2,3-*d*]-pyrimidines and pyrrolo[3,4-*b*]-quinoxalines were among the synthesized compounds that presented this kind of biological activity. Researchers also reported some 2-sulphonyl quinoxalines and 3-[(alkylthio) methyl] quinoxaline-1-oxide derivatives as compounds with high antifungal activity [4], and also pyrazolo quinoxalines which were observed to be active against fungal infections [19].

There are quinoxaline derivatives that present anti-protozoan activity [20,21], especially anti-amoebic [22-24], against *Plasmodium* and *Leishmania* species (strain MHOM/BR/76/LTB-012A) [21,25]. Compounds with one halogenous group in position 6 and 7 of the quinoxaline core provide an efficient approach for further development of antimalarial and antileishmanial agent [21].

Quinoxaline derivatives present other biological properties. Anti-cancer activity has been already studied [26-28], and results obtained are very promising. Recently, our research group has demonstrated anti-proliferative activity in several cancer cell lines.

Antioxidant and anti-inflammatory activity has also been explored for quinoxaline derivatives [29-31]. Some compounds presented anti-inflammatory effect similar to the reference drug used, indomethacin [29].

Some copper and zinc quinoxaline derivative complexes have presented antidiabetic activity [32] and N-arylcarbamoyl and N-aryl thiocarbamoyl derivatives revealed hypoglycemic behavior in Wistar rats.

Quinoxaline-5,8-diones derivatives were tested for their inhibitory

activity on rat aortic smooth muscle cell proliferation and results revealed good proliferation inhibition. Thus the quinoxaline-5,8-diones were found as promising anti-atherosclerotic agents [16,19,33].

New series of structurally novel 3-substituted-2-carboxamides quinoxaline exhibited 5-HT₃ (serotonin) receptor antagonism, and some of them showed antagonism greater than the standard TCA (Tricyclic anti-depressant) drugs [34].

A series of 7-heterocycle-substituted quinoxaline carboxylic acids were tested for their neuroprotective efficacy. One of the synthesized compounds was found to possess high neuroprotective effect *in vitro* and showed excellent *in vivo* activity [35].

Due to the wide range of applications, quinoxaline derivative compounds have aroused the interest of the scientific community, especially in the last decade. Given the ability to design different structures from the quinoxaline core, improvement of biological activities may be achieved, as well as new applications.

References

- Loriga M, Vitale G, Paglietti G (1998) Quinoxaline chemistry - Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafoolic acid (CB 3717) and its precursors. Synthesis and evaluation of *in vitro* anticancer activity. *Farmacol* 53: 139-149.
- Tandon VK, Yadav DB, Maurya HK, Chaturvedi AK, Shukla PK (2006) Design, synthesis, and biological evaluation of 1,2,3-trisubstituted-1,4-dihydrobenzo[g] quinoxaline-5,10-diones and related compounds as antifungal and antibacterial agents. *Bioorg Med Chem* 14: 6120-6126.
- Kalinin AA, Voloshina AD, Kulik NV, Zobov VV, Mamedov VA (2013) Antimicrobial activity of imidazo[1,5-*a*]quinoxaline derivatives with pyridinium moiety. *Eur J Med Chem* 66: 345-354.
- Carta A, Paglietti G, Rahbar Nikookar ME, Sanna P, Sechi L, et al. (2002) Novel substituted quinoxaline 1,4-dioxides with *in vitro* antimycobacterial and anti-candida activity. *Eur J Med Chem* 37: 355-366.
- Sanna P, Carta A, Loriga M, Zanetti S, Sechi L (1999) Preparation and biological evaluation of 6/7-trifluoromethyl(nitro)-, 6,7-difluoro-3-alkyl (aryl)-substituted-quinoxalin-2-ones. Part 3. *Farmacol* 54: 169-177.
- Khan SA, Saleem K, Khan Z (2007) Synthesis, characterization and *in vitro* antibacterial activity of new steroidal thiazolo quinoxalines. *Eur J Med Chem* 42: 103-108.
- Ramalingam P, Ganapathy S, Rao ChB (2010) *In vitro* antitubercular and antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones. *Bioorg Med Chem Lett* 20: 406-408.

*Corresponding author: Ricardo Ferraz, Ciências Químicas e Biomoléculas, Escola Superior de Tecnologia da Saúde – Instituto Politécnico do Porto, Rua Valente Perfeito, 322, 4400-330 Porto, Portugal, Tel: +351222061000; E-mail: ricardoferraz@eu.ipp.pt

Received February 19, 2014; Accepted February 20, 2014; Published February 28, 2014

Citation: Vieira M, Ferraz R, Fernandes R, Prudêncio C (2014) New Quinoxalines with Biological Applications. *Biochem Pharmacol* 3: e152. doi:[10.4172/2167-0501.1000e152](https://doi.org/10.4172/2167-0501.1000e152)

Copyright: © 2014 Vieira M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

8. Ishikawa H, Sugiyama T, Kurita K, Yokoyama A (2012) Synthesis and antimicrobial activity of 2,3-bis(bromomethyl)quinoxaline derivatives. *Bio org Chem* 41-42: 1-5.
9. Jaso A, Zarranz B, Aldana I, Monge A (2003) Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-*Mycobacterium tuberculosis* agents. *Eur J Med Chem* 38: 791-800.
10. Vicente E, Villar R, Burguete A, Solano B, Pérez-Silanes S, et al. (2008) Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. *Antimicrob Agents Chemother* 52: 3321-3326.
11. Segreti J, Goodman LJ, Trenholme GM (1993) in-vitro activity of new quinoxaline compounds against campylobacter species and clostridium-difficile. *Diagn Microbiol Infect Dis* 17: 177-179.
12. Khan SA, AsiriAM (2011) Synthesis of novel steroidal oxazoloquinoxaline as antibacterial agents. *Arabian Journal of Chemistry* 4: 349-354.
13. Vieira M, Pinheiro C2, Fernandes R3, Noronha JP4, Prudêncio C5 (2013) Antimicrobial activity of quinoxaline 1,4-dioxide with 2- and 3-substituted derivatives. *Microbiol Res* .
14. Zanetti S, Sechi LA, Molicotti P, Cannas S, Bua A, et al. (2005) *In vitro* activity of new quinoxalin 1,4-dioxide derivatives against strains of *Mycobacterium tuberculosis* and other mycobacteria. *Int J Antimicrob Agents* 25: 179-181.
15. Antonio Carta, Michele Palomba, Giuseppe Paglietti, Paola Molicotti, Bianca Paglietti, et al. (2007) [1,2,3]Triazolo[4,5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant *Mycobacterium tuberculosis* strains. *Bioorg Med ChemLett*17: 4791-4794.
16. Asif Husain, Diwakar Madhesia (2011) Recent advances in pharmacological activities of quinoxalinederivates. *Journal of pharmacy research* 4: 924-929.
17. Patidar A, Jeyakandan M, Mobjiya A, Selvam G (2011) Exploring potential of quinoxaline moiety. *International Journal of Pharm Tech Research* 3: 386-392.
18. Ammar YA, Ismail MMF, El-Gaby MSA, Zahran MA (2002) Some reactions with quinoxaline-2,3-dicarboxylic acid anhydride: Novel synthesis of thieno[2,3-d]pyrimidines and pyrrolo[3,4-b]quinoxalines as antimicrobial agents. *Indian Journal of Chemistry* 41B: 1486-1491.
19. Deepika Y., N.P., Sachin K., Shewta S., Biological activity of quinoxaline derivatives. *International Journal of Current Pharmaceutical Review and Research*, 2011. 1(3): p. 33-46.
20. Torres E, Moreno-Viguri E, Galiano S, Devarapally G, Crawford PW, et al. (2013) Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents. *Eur J Med Chem* 66: 324-334.
21. Barea C, Pabón A, Castillo D, Zimic M, Quiliano M (2011) New salicylamide and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial and antimalarial activities. *Bio org Med Chem Lett* 21: 4498-4502.
22. Budakoti A, Bhat AR, Azam A (2009) Synthesis of new 2-(5-substituted-3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]quinoxaline derivatives and evaluation of their antiamoebic activity. *Eur J Med Chem* 44: 1317-1325.
23. Abid M, Azam A (2006) Synthesis, characterization and antiamoebic activity of 1-(thiazolo[4,5-b]quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives. *Bioorg Med Chem Lett* 16: 2812-2816.
24. Duque-Montaño BE, Gómez-Caro LC, Sanchez-Sanchez M, Monge A, Hernández-Baltazar E, et al. (2013) Synthesis and *in vitro* evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against *Entamoeba histolytica*. *Bioorg Med Chem* 21: 4550-4558.
25. Barea C, Pabón A, Galiano S, Pérez-Silanes S, Gonzalez G, et al. (2012) Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxamido) quinoxaline 1,4-dioxide derivatives. *Molecules* 17: 9451-9461.
26. Piras S, Loriga M, Paglietti G (2004) Quinoxaline chemistry. Part XVII. Methyl 4-(substituted 2-quinoxalinyloxy) phenyl acetates and ethyl N-(4-(substituted 2-quinoxalinyloxy) phenyl acetyl) glutamates analogs of methotrexate: synthesis and evaluation of *in vitro* anticancer activity. *Farmaco* 59: 185-194.
27. Galal, S.A.Galal SA, Abdelsamie AS, Soliman SM, Mortier J, Wolber G, et al. (2013) Design, synthesis and structure–activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor. *European Journal of Medicinal Chemistry* 69: 115-124.
28. Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-quinoxalines: search for anticancer agent. *Eur J Med Chem* 65: 168-186.
29. Asunción Burguete, Eleni Pontiki, Dimitra Hadjipavlou-Litina, SaioaAncizu, Raquel Villar, et al. (2011) Synthesis and Biological evaluation of New Quinoxaline Derivatives as Antioxidant and Anti-Inflammatory Agents. *ChemBiol Drug Des* 77: 255-267.
30. Torres E, Moreno E, Ancizu S, Barea C, Galiano S (2011) New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-*Mycobacterium tuberculosis* agents. *Bioorg Med ChemLett*21: 3699-3703.
31. Abu-Hashem AA, Gouda MA, Badria FA (2010) Synthesis of some new pyrimido [2',1':2,3]thiazolo[4,5-b]quinoxaline derivatives as anti-inflammatory and analgesic agents. *Eur J Med Chem* 45: 1976-1981.
32. Naveen V Kulkarni, Vidyanand K Revankar, Kirasur BN, Mallinath H Hugar (2012) Transition metal complexes of thiosemi carbazones with quinoxaline hub: an emphasis on antidiabetic property. *Medicinal Chemistry Research* 21: 663-671.
33. Chung HJ, Jung OJ, Chae MJ, Hong SY, Chung KH, et al. (2005) Synthesis and biological evaluation of quinoxaline-5,8-diones that inhibit vascular smooth muscle cell proliferation. *Bio org Med Chem Lett* 15: 3380-3384.
34. Mahesh R, Devadoss T, Pandey DK, Bhatt S (2011) Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides. *Bio org Med Chem Lett* 21: 1253-1256.
35. Takano Y, Shiga F, Asano J, Ando N, Uchiki H, et al. (2003) Synthesis and AMPA receptor antagonistic activity of a novel class of quinoxaline carboxylic acid with a substituted phenyl group at the C-7 position. *Bioorg Med Chem Lett* 13: 3521-3525.